A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT03018665
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Registry
-
NCT03018665
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- Not reported
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT03018665. Randomized; no masking; primary purpose treatment. Start 2017-02 (registry gives no type); primary completion 2021-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Exenatide
- Intervention (Drug)
- BIAsp30
- Intervention (Drug)
- Metformin
- Lead sponsor
- The First Hospital of Jilin University
Record details
- Record id
cardio:ct-nct03018665- Content hash
bee22796dfa46ccfe426a7bca655c537190801af7d8539ee76324249cab48275